Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06342310 · ClinicalTrials.gov registry record · Phase 2
RE104 Safety and Efficacy Study in Postpartum Depression
A Phase 2 study, sponsored by Reunion Neuroscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT06342310: Completed Phase 2 study, sponsored by Reunion Neuroscience.
NCT06342310 is a Phase 2 study that has completed, run by Reunion Neuroscience. The registered enrollment target is 84 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06342310, a Phase 2 study, has completed, sponsored by Reunion Neuroscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
Primary Outcome
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.
Interventions
- DRUG RE104 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 2 |
What the finished NCT06342310 record still lists
NCT06342310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 1 intervention - of which RE104 for Injection is the first listed.
NCT06342310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06342310 about?
NCT06342310 is a clinical study titled "RE104 Safety and Efficacy Study in Postpartum Depression". The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
What is the current status of trial NCT06342310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2024-06-14. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT06342310?
The interventions under investigation include: RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT06342310?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06342310's enrollment target sits among peer trials
84 822nd of 2000 higher than 1,173 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI